Trials / Unknown
UnknownNCT04303247
CD19 and CD22 Dual-targeted CAR-T Cells for Relapsed or Refractory B-NHL
CD19 and CD22 Dual-targeted CAR-T Cells for Relapsed or Refractory B-NHL: a Multi-center, Uncontrolled Trial.
- Status
- Unknown
- Phase
- EARLY_Phase 1
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- Sponsor
- Xinqiao Hospital of Chongqing · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
Although the anti-CD19 CAR-T cell therapies have gained significant results in patients with relapsed and refractory B-cell hematologic malignancies. There are patients who resisted anti-CD19 CAR-T cells or with CD19 negative relapse. To make further improvement, combining CD19 and CD22 as dual-targets for CAR-T cells, which adapt the FasT CAR-T cells manufacture technology to shorten the manufacture time and maintain the stemness of CAR-T cells. We launch such a clinical trial using CD19 and CD22 targeted CAR-T cells for patients with relapsed and refractory B-cell NHL to evaluate the efficacy and safety of CD19 and CD22 targeted CAR-T cell therapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | CD19 and CD22 targeted CAR-T cells | The T cells aphesis from subjects then been manufactured to express CAR to binding CD19 and CD22 on B-cell lymphoma. |
Timeline
- Start date
- 2020-05-01
- Primary completion
- 2021-05-01
- Completion
- 2023-05-01
- First posted
- 2020-03-11
- Last updated
- 2020-03-11
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04303247. Inclusion in this directory is not an endorsement.